Who are RBP-7000's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methylphenidate, aripiprazole, and combination, Risperdal,reminyl, Crushed ticagrelor, morphine,metoclopramide, aripiprazole long acting injectable formulation, Standard of Care Oral antipsychotics, Abilify Maintena.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rbp-7000.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RBP-7000 — Competitive Intelligence Brief

RBP-7000 (RBP-7000) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic, long-acting injectable. Area: Psychiatry.

phase 3 Atypical antipsychotic, long-acting injectable Dopamine D2 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

RBP-7000 (RBP-7000) — Indivior Inc.. RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RBP-7000 TARGET	RBP-7000	Indivior Inc.	phase 3	Atypical antipsychotic, long-acting injectable	Dopamine D2 receptor
Methylphenidate, aripiprazole, and combination	Methylphenidate, aripiprazole, and combination	Tri-Service General Hospital	marketed	Stimulant and atypical antipsychotic combination	Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor
Risperdal,reminyl	Risperdal,reminyl	Jinan Mental Hospital	marketed	Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl)	Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)
aripiprazole long acting injectable formulation	aripiprazole long acting injectable formulation	Vanguard Research Group	marketed	Atypical antipsychotic (dopamine partial agonist)	Dopamine D2 receptor, Dopamine D3 receptor
Standard of Care Oral antipsychotics	Standard of Care Oral antipsychotics	University of Utah	marketed	Antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Abilify Maintena	Abilify Maintena	Gazda, Thomas D., M.D., PC	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist); serotonin 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic, long-acting injectable class)

Indivior Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RBP-7000 — Competitive Intelligence Brief. https://druglandscape.com/ci/rbp-7000. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab